A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To
Public ClinicalTrials.gov record NCT00232154. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Study Of Azithromycin Pharmacokinetics In Sinus Mucosal Tissue And Plasma In Subjects With Chronic Rhinosinusitis Following A Single 2g Dose Of Azithromycin Extended Release For Oral Suspension Or Azithromycin 500mg Tablet Formulation Once Daily For A Maximum Of Three Days
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To measure the level of drug in nasal tissue and blood after taking a single 2g dose or 500mg tablets for up to 3 days.
Study identification
- NCT ID
- NCT00232154
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Interventions
- Zithromax™ (azithromycin) 500mg tablets Drug
- Endoscopic Sinus Surgery Procedure
- Blood sampling for hematology Procedure
- Blood sampling for plasma chemistry profile Procedure
- Serum pregnancy test (for women of child-bearing potential) Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2005
- Primary completion
- May 31, 2006
- Completion
- May 31, 2006
- Last update posted
- Apr 20, 2011
2005 – 2006
United States locations
- U.S. sites
- 18
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Alabaster | Alabama | 35007 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35209 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35233 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35242 | — |
| Pfizer Investigational Site | Hoover | Alabama | 35216 | — |
| Pfizer Investigational Site | Hoover | Alabama | 35244 | — |
| Pfizer Investigational Site | Fresno | California | 93720 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32216 | — |
| Pfizer Investigational Site | Miami | Florida | 33136-1002 | — |
| Pfizer Investigational Site | Augusta | Georgia | 30912 | — |
| Pfizer Investigational Site | Elgin | Illinois | 60120 | — |
| Pfizer Investigational Site | Elgin | Illinois | 60123 | — |
| Pfizer Investigational Site | Maywood | Illinois | 60153 | — |
| Pfizer Investigational Site | Carrollton | Kentucky | 41008 | — |
| Pfizer Investigational Site | La Grange | Kentucky | 40031 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40207 | — |
| Pfizer Investigational Site | Durham | North Carolina | 27710 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00232154, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2011 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00232154 live on ClinicalTrials.gov.